5.4 Biofilm Progression & Systemic Infection Re-evaluation
Key Takeaways
- Over 60% to 80% of chronic non-healing wounds harbor surface biofilms—polymicrobial communities enclosed within a protective extracellular polymeric substance (EPS) matrix resistant to systemic antibiotics.
- The NERDS acronym identifies localized wound infection/biofilm: Non-healing wound, Exudate increase, Red friable granulation, Debris/slough, Smell/odor (treated with topical antimicrobials).
- The STONEES acronym identifies systemic infection/deep tissue spread: Size increasing, Temperature >3 degrees F differential, Os/bone exposed, New areas of breakdown, Erythema/edema >2 cm, Exudate purulent, Smell/odor (requires systemic antibiotics).
- Clinical suspicion of deep tissue infection or sepsis warrants immediate workup: quantitative tissue biopsy (>10⁵ CFU/g), blood cultures, inflammatory markers (CRP >10-20 mg/L, ESR >50 mm/hr), and complete blood count (CBC).
- Effective biofilm management requires anti-biofilm stewardship: mechanical sharp debridement (disrupting EPS), followed immediately by topical broad-spectrum antimicrobials (cadexomer iodine, silver, hypochlorous acid) and surfactant cleansers.
Biofilm Progression & Systemic Infection Re-evaluation
Wound infection exists along a dynamic continuum ranging from benign contamination to life-threatening systemic sepsis. One of the primary causes of chronic wound stagnation is the presence of surface biofilms—complex, polymicrobial communities embedded within a self-produced extracellular polymeric substance (EPS) matrix. Re-evaluating infection status requires distinguishing between localized superficial bioburden/biofilm and invasive deep tissue or systemic infection, ensuring precise antimicrobial stewardship.
The Wound Infection Continuum
Clinical infection evolves across five recognized stages:
- Contamination: Non-replicating organisms present on the wound surface without host tissue injury or immune response.
- Colonization: Replicating microorganisms present on the wound surface without causing clinical tissue damage or systemic host response.
- Local Infection / Biofilm (Critical Colonization): Microorganisms multiply, forming protective biofilms or localized microcolonies that provoke a localized inflammatory response, stalling healing without deep tissue invasion.
- Spreading / Deep Tissue Infection: Microorganisms invade surrounding healthy tissue, fascial planes, or deeper structures (tendon, muscle, bone), provoking local warmth, spreading erythema (> 2 cm), induration, and purulence.
- Systemic Infection / Sepsis: Microorganisms or their toxins enter the bloodstream, triggering systemic inflammatory response syndrome (SIRS), bacteremia, multi-organ failure, and septic shock.
Biofilm Pathophysiology & Structural Defense
Biofilms are present in over 60% to 80% of chronic non-healing wounds, compared to less than 6% of acute wounds. Biofilm lifecycle consists of three continuous phases:
- Attachment: Planktonic (free-floating) bacteria adhere to fibronectin and collagen within the wound bed.
- EPS Matrix Synthesis: Attached bacteria produce an extracellular polymeric substance (EPS) composed of polysaccharides, extracellular DNA (eDNA), proteins, and lipids. This EPS shield acts as a formidable physical barrier.
- Phenotypic Resistance & Quorum Sensing: Bacteria within biofilms enter a low-metabolic state ("persister cells"), becoming up to 100 to 1,000 times more resistant to systemic antibiotics and host antibodies than their planktonic counterparts. Through quorum sensing (chemical signaling), bacteria coordinate virulence factor release and disperse planktonic progeny to seed adjacent tissue.
BIOFILM DEVELOPMENT PHASES
Planktonic Initial EPS Matrix Production Dispersal of
Bacteria Attachment & Quorum Sensing Planktonic Progeny
o o o --> o o o --> +-------------------+ --> o o o
~~~~~~~ ~~~~~~~ | (EPS Matrix) | ~~~~~~~~
Wound Bed Wound Bed | O O O O | Wound Bed
+-------------------+
Clinical Diagnostic Frameworks: NERDS vs. STONEES
To standardize clinical decision-making and prevent inappropriate systemic antibiotic overuse, Sibbald et al. validated two complementary clinical diagnostic tools:
1. NERDS (Signs of Localized Infection / Biofilm Bioburden)
Presence of 3 or more NERDS signs indicates localized infection limited to the superficial wound bed. Management requires topical antimicrobial interventions.
- N: Non-healing wound (stalled PAR trajectory).
- E: Exudate increase (change in volume or character).
- R: Red, friable hypergranulation tissue (bleeds easily upon light probe contact).
- D: Debris / slough re-accumulation on wound surface.
- S: Smell / foul odor generated by bacterial metabolic byproducts.
2. STONEES (Signs of Deep / Systemic Tissue Infection)
Presence of 3 or more STONEES signs indicates invasive deep tissue infection extending into underlying muscle, fascia, or bone. Management requires systemic antibiotic therapy and urgent diagnostic workup.
- S: Size increasing (wound expansion).
- T: Temperature elevation (> 3°F / 1.7°C differential compared to contralateral anatomical site).
- O: Os (exposed bone palpated with sterile probe / positive PTB).
- N: New areas of satellite breakdown or tissue necrosis.
- E: Erythema and edema extending > 2 cm from wound margins.
- E: Exudate purulent (thick, opaque, yellow/green/brown pus).
- S: Smell / persistent malodor.
Laboratory & Diagnostic Microbiology Workup
When STONEES criteria are met or deep tissue sepsis is suspected, immediate lab workup is required:
- Wound Microbiological Sampling:
- Levett's Levine Swab Technique: Cleanse wound with sterile saline and debride surface slough. Press swab tip firmly onto a 1 cm² area of clean granulating tissue, rotating to express tissue fluid. (Superior to superficial swab of pus/debris).
- Quantitative Tissue Biopsy (Gold Standard): Full-thickness tissue specimen homogenized and cultured. Microbial counts > 10⁵ CFU/g (or any growth of beta-hemolytic Streptococcus) confirm invasive tissue infection.
- Systemic Inflammatory & Hematologic Markers:
- C-Reactive Protein (CRP): Elevated levels (> 10 - 20 mg/L) indicate active systemic inflammation; highly responsive to antimicrobial resolution.
- Erythrocyte Sedimentation Rate (ESR): Values > 50 - 70 mm/hr strongly correlate with underlying osteomyelitis in diabetic foot ulcers.
- Complete Blood Count (CBC): Leukocytosis (WBC > 12,000/µL) with left shift (bandemia > 10%) indicates acute systemic immune response.
- Blood Cultures: Mandatory if fever (> 38.0°C), hypothermia (< 36.0°C), hypotension, or rigors are present.
Anti-Biofilm Stewardship Protocol
Systemic antibiotics alone cannot penetrate an intact EPS biofilm matrix. Effective anti-biofilm stewardship follows the "Debride, Cleanse, Treat" cycle:
- Mechanical Disruption (Debridement): Sharp surgical debridement physically disrupts the EPS matrix, converting resistant biofilm bacteria back into susceptible planktonic phenotypes.
- Surfactant Cleansing: Wound cleansing with surfactant-containing solutions (e.g., propylbetaine-poloxamer, hypochlorous acid) lowers surface tension to detach disrupted matrix fragments.
- Topical Biofilm Suppressors: Apply broad-spectrum topical antimicrobials within the 24- to 48-hour post-debridement therapeutic window before EPS matrix re-formation occurs:
- Cadexomer Iodine: Slowly releases 0.9% iodine while absorbing exudate; proven to penetrate and eradicate biofilm matrices.
- Ionic Silver / Medical Honey / PHMB: Sustained-release silver foam/gelling fibers, Leptospermum honey, or polyhexamethylene biguanide dressings.
| Domain | NERDS (Local Infection / Biofilm) | STONEES (Deep / Systemic Infection) |
|---|---|---|
| Infection Level | Superficial wound bed / Critical bioburden | Deep tissue invasion (muscle, fascia, bone) |
| Clinical Signs | Non-healing, Exudate increase, Red friable tissue, Debris, Smell | Size increasing, Temp > 3°F, Os/bone exposed, New breakdown, Erythema > 2 cm, Exudate purulent, Smell |
| Diagnostic Threshold | >= 3 NERDS criteria present | >= 3 STONEES criteria present |
| Microbiology Modality | Levine swab technique after wound cleansing | Quantitative tissue biopsy (> 10⁵ CFU/g), Blood cultures, MRI |
| Inflammatory Labs | Typically normal CRP, ESR, and WBC | Elevated CRP (> 20 mg/L), ESR (> 50 mm/hr), Leukocytosis |
| Primary Treatment | Sharp debridement + Topical antimicrobials (cadexomer iodine, silver) | Surgical incision/debridement + Systemic oral/IV antibiotics |
A 62-year-old patient with a chronic venous leg ulcer presents with stalled healing, increased serous exudate, dark red friable granulation tissue that bleeds easily, and recurrent surface slough. Periwound erythema is <0.5 cm, and the patient is afebrile. How should this infection state be categorized and treated?
Why are systemic oral or intravenous antibiotics ineffective as a monotherapy for treating established chronic wound biofilms?
A diabetic patient presents with a deep neuropathic heel ulcer. Clinical exam reveals periwound erythema extending 4.5 cm from the wound margins, localized skin temperature 4.2 degrees F higher than the uninjured heel, thick purulent drainage, and a probe-to-bone test that contacts solid bone. Laboratory evaluation reveals an ESR of 82 mm/hr and CRP of 45 mg/L. What is the indicated management strategy?